NovalGen is a clinical-stage biotechnology company advancing breakthrough multi-specific biologics to transform outcomes in oncology, autoimmune, haematological, and metabolic disorders
We harness the potential of our proprietary AutoRegulation (AR) platform technology to develop highly regulated biologics, providing safer and more potent therapeutic options for patients.
Our history
Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovation from UCL, London UK.
Our values
NovalGen is guided by our core set of values. The culture of NovalGen reflects these values and they help guide our decisions.
